Deals this week: OptiNose, Dermira, Aadi Bioscience

11th May 2017 (Last Updated May 11th, 2017 18:30)

OptiNose has completed a series D venture financing round to raise funds required for the commercialisation and launch of its lead product candidate, OPN-375, in the US.

OptiNose has completed a series D venture financing round to raise funds required for the commercialisation and launch of its lead product candidate, OPN-375, in the US.

Based in Norway, OptiNose is a commercial-stage ENT / Allergy pharmaceutical company.

The company has raised $37m through the round.

US-based biopharmaceutical company Dermira has announced the pricing for its convertible senior notes offering to raise $250m in gross proceeds.

Due 15 May 2022, the notes will carry a coupon rate of 3%.

Initial purchasers of the notes will be granted a 30-day option to purchase up to an additional $37.5m-worth notes in aggregate principal amount.

The interest on the notes will be payable semi-annually, while the holders will have option to convert the notes into shares of common stock of the company, upon maturity.

The proceeds are intended to be used for general corporate purposes, including working capital, meeting capital expenditure, and business expansion.

"US-based biopharmaceutical company Dermira has announced the pricing for its convertible senior notes offering to raise $250m in gross proceeds."

Aadi Bioscience has completed a series A venture financing round to raise $23m in order to fund its clinical programmes for its albumin-bound mTOR inhibitor candidate, ABI-009.

Based in the US, Aadi Bioscience is a clinical-stage biopharmaceutical company.

G1 Therapeutics has announced an initial public offering (IPO) of 6.25 million shares of its common stock with a 30-day option to underwriters to purchase up to an additional 937,500 shares.

The proceeds are intended to be utilised for advancing the development of its drug candidates trilaciclib, G1T38 and G1T48, working capital and general corporate purposes, as well as to explore opportunities for organic growth and investment.

G1 Therapeutics is a clinical-stage biopharmaceutical company based in the US.

US-based biotechnology company Fulcrum Therapeutics has raised additional funds through a series A venture financing round from GV, following a $55m funding from Third Rock Ventures in June 2016.

The additional funds will be invested to advance the company’s lead programmes in Fragile X syndrome (FXS) and Fascioscapularhumeral muscular dystrophy (FSHD).